Gaudium IVF and Women Health IPO: A look at strengths and risks from RHP

Gaudium IVF and Women Health IPO: The initial public offering of fertility services provider Gaudium IVF and Women Health, which is open from February 20 to February 24, has fixed a price band of ₹75 to ₹79 per share.

The ₹165 crore initial share sale is a mix of a fresh issue of ₹90 crore and an offer for sale of ₹75 crore by promoter Dr Manika Khanna.

Proceeds from the fresh issue will be used for capital expenditure of ₹50 crore to establish 19 new IVF centres, debt repayment of ₹20 crore, and for general corporate purposes.

Gaudium IVF and Women Health IPO: A look at its strengths from RHP

• The company has a patient-centric approach. It has counsellors to guide patients on their parenthood journey with emotional support and care. It also provides patients with quality consultation, complete transparency, confidentiality and support throughout their IVF journey.
• It has experienced doctors, embryologists, and gynaecologists led by Dr Manika Khanna for providing specialised expertise to its patients in IVF procedures.
• With more than 30 locations, the company has established itself as a trusted name in fertility treatment across India.
• It provides world-class treatment by using the latest technology, like next-generation laboratories featuring INTEGRA Ti, for ICSI procedures. It also uses the latest machinery for egg quality evaluation, precise monitoring using Samsung ultrasound machines and advanced clean operating rooms to keep everything sterile.
• Gaudium IVF and Women Health follows an asset-light model, characterised by efficient standard operating procedures and internal controls, lowering dependency on individual practitioners and enabling scalable, consistent care across its network.

Gaudium IVF and Women Health IPO: Risks

• Gaudium IVF provides healthcare services, mainly rendering various fertility treatments such as intrauterine insemination (IUI), in vitro fertilisation (IVF), egg freezing, intracytoplasmic sperm injection (ICSI) and laser-assisted embryo implantation, amongst others, and is subject to various operational, medical and legal risks linked to operations of healthcare services. Any inability to provide quality healthcare could adversely affect the financial performance of the company.
• The business is highly dependent on doctors, nurses and other healthcare professionals. If the company is unable to attract such professionals, it can affect business.
• It has entered, and will continue to enter, into related party transactions which can potentially involve conflicts of interest.
• The company is dependent on a limited number of embryologists, and the loss of or inability to attract or retain such specialists could affect business and financial condition.
• The business of Gaudium IVF and Women Health depends on the strength of the company's brand and reputation. Failure to maintain and enhance the brand can affect business.

Gaudium IVF and Women Health IPO GMP